BIO hosting virtual summit to coordinate industry COVID-19 response
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BIO is hosting a two-day virtual summit with companies that are developing COVID-19 medical countermeasures, government officials and other stakeholders.
In addition to biopharma company representatives, White House Coronavirus Task Force Response Coordinator Deborah Birx; Robert Kadlec, HHS assistant secretary for preparedness and response; and other government officials have been invited to participate in the March 24-25 event.
The summit will be led by BIO President and CEO Jim Greenwood and George Scangos, president and CEO of Vir Biotechnology Inc. (NASDAQ:VIR).
More than 45 BIO member companies are developing COVID-19 countermeasures, according to the trade association.
The global biopharmaceutical industry has responded to the pandemic with unprecedented speed and intensity.
Readouts from almost 30 clinical trials of repurposed medicines are expected by April 30 (see “First Up for COVID-19: Nearly 30 Clinical Readouts Before End of April”).
At least 57 companies, academic groups and government organizations are developing vaccines, and at least 19 companies are creating new COVID-19 therapies (see “COVID-19: A Growing List of New Vaccines and Therapies in Development”).
Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus.